来自 #ESMO26 & @NEJM
Tarlatamab–Durvalumab 维持治疗广泛期小细胞肺癌
https://www.nejm.org/doi/full/10.1056/NEJMoa2609482
对于这种可怕的疾病，这是能够改变临床实践的数据，风险比明确无误。
200 浏览 · 2 赞 · 2 转发 · 1 回复
Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgCytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org- Anirban Maitra@Aiims1742
Practice-changing new lung cancer immunotherapy improves survival https://www.nbcnews.com/health/cancer/lung-cancer-immunotherapy-tarlatamab-improves-survival-rcna604903
来源：Anirban Maitra · x.com